Clinical trials: High-Risk Cancer
Lymphoma
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00004169
- Testing
- carboplatin, cyclophosphamide, etoposide
- Where
- United States
- Sponsor
- Northwestern University
Prostate Cancer
Robotic Telesurgery in Urology
The goal of this clinical trial is to confirm the safety and feasibility of robotic telesurgery when used for the surgical management of prostate cancer in participates undergoing treatment for prostate cancer.
- Trial name
- NCT07541066
- Testing
- High-Intensity Focused Ultrasound (HIFU) robotic device
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
AML, ALL
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic…
- Conditions
- AML, ALL, MDS, MPD Withou Myelofibrosis
- Trial name
- NCT04644016
- Testing
- Clofarabine, Fludarabine, Busulfan
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Glioma
Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma
The objective of this study is to determine the survival status of patients enrolled in study GLI01S (all-case observational study).
- Trial name
- NCT02300506
- Testing
- No intervention
- Where
- 2 sites in Japan
- Volunteers
- 507 people
- Sponsor
- Eisai Co., Ltd.
Neuroblastoma
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine (MIBG), may carry radiation directly to tumor cells and not harm normal cells.
- Trial name
- NCT00659984
- Testing
- UltratraceTM Iobenguane I 131 Imaging, UltratraceTM Iobenguane I 131 Therapy
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
AML (Acute Myeloid Leukemia)
Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia
The study is a multicentric, interventional study that evaluates the efficacy of allogeneic HLA-matched allo-HSCT consisting of myeloablative conditioning coupled with donor Treg/Tcon adoptive immunotherapy for high-risk AML…
- Trial name
- MATCH-Treg (NCT07552649)
- Testing
- HSCT with Treg/Tcon adoptive immunotherapy
- Where
- 2 sites in Italy
- Volunteers
- 28 people
- Sponsor
- Antonio Pierini
Diffuse Large B Cell Lymphoma (DLBCL)
Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.
This is a retrospective analysis of the presence of chromosomal rearrangements involving MYC, BCL2 and BCL6 genes by FISH in a retrospective, single-center series of large B-cell lymphomas, in order to allow a better…
- Trial name
- CHARTHER (NCT07181785)
- Testing
- Treatments: anthracycline-based combinations followed or not by involved-field radiotherapy
- Where
- Italy
- Volunteers
- 555 people
- Sponsor
- Andrés José Maria Ferreri
Cervical Intraepithelial Neoplasia
A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions
This is a Phase II study to evaluate the efficacy and safety of a human papilloma virus (HPV) therapeutic vaccine called PepCan (HPV 16 E6 peptides combined with Candida skin testing reagent called Candin®) in adult females over…
- Trial name
- NCT02481414
- Testing
- PepCan, Candin®
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Arkansas
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
VERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and safety of PDS0101 administered in combination with pembrolizumab in adults with HPV16 and PD-L1 positive recurrent or metastatic head and neck squamous…
- Conditions
- Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
- Trial name
- VERSATILE002 (NCT04260126)
- Testing
- Pembrolizumab (KEYTRUDA®) and PDS0101
- Where
- 23 sites in United States, Ireland and 2 more
- Volunteers
- 95 people
- Sponsor
- PDS Biotechnology Corp.
Prostate Carcinoma
Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
The purpose of this study is to evaluate the dose of High Dose Rate (HDR) brachytherapy chosen for this study as well as a commonly used alternate form of brachytherapy called low dose rate (or seed) brachytherapy.
- Trial name
- NCT02960087
- Testing
- Low dose rate brachytherapy, High dose rate brachytherapy
- Where
- 7 sites in Canada
- Volunteers
- 334 people
- Sponsor
- Canadian Cancer Trials Group
Glioma, Glioblastoma Multiforme
Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma
The pupose of this study is to demonstrate the safety of the Litx™ therapy and confirm the zone of tumor destruction with escalated light doses following intraoperative treatment of primary or recurrent glioma.
- Conditions
- Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma
- Trial name
- NCT00409214
- Testing
- LS11 (talaporfin sodium), Light source (interstitial light emitting diodes), Intraoperative placement of device in glioma
- Where
- Serbia
- Volunteers
- 18 people
- Sponsor
- Light Sciences Oncology
Neuroblastoma
131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma
This trial is studying how well iodine I 131 metaiodobenzylguanidine together with combination chemotherapy works in treating patients who are undergoing an autologous peripheral stem cell for high risk or relapsed neuroblastoma.
- Trial name
- NCT00798148
- Testing
- 131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation
- Where
- 2 sites in Iran
- Volunteers
- 10 people
- Sponsor
- Tehran University of Medical Sciences
Nonmuscle-invasive Bladder Cancer
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.
- Trial name
- NCT06971614
- Testing
- T3011
- Where
- 9 sites in United States
- Volunteers
- 160 people
- Sponsor
- ImmVira Pharma Co. Ltd
Mantle Cell Lymphoma
CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma
First-line CAR-T-cell consolidation after an abbreviated induction with 2 cycles of Rituximab and Ibrutinib prior to CAR-T-cell treatment and followed by 6 months of maintenance with Ibrutinib in patients with high risk MCL.
- Trial name
- CARMAN (NCT06482684)
- Testing
- KTE-X19, Ibrutinib
- Where
- 2 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Christian Schmidt, MD
Intrahepatic Cholangiocarcinoma (Icc), Perihilar Cholangiocarcinoma
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Among resectable biliary tract cancers (BTC) patients, surgery has historically been the standard treatment, but even with curative surgery, the cure rates remain relatively low, with most patients relapsing in the short term and…
- Trial name
- NCT06739252
- Testing
- Gemcitabine Oxaliplatin and 5FU
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Peking University
DNA, Cancer
Optimization of Radiation Protection Through Genomic Analyses
The long-term goal is to define "signatures" in the form of genomic changes through sequence analyses of genomic DNA using modern Next Generation Sequencing (NGS) methods, which 1. determine the radiation exposure of humans. 2.
- Conditions
- DNA, Cancer, Radiation
- Trial name
- ORtogether (NCT06253338)
- Testing
- genomic alterations
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital, Essen
Metastatic Melanoma, Recurrent Melanoma
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II trial studies how well aldesleukin with or without ziv-aflibercept works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7
- Trial name
- NCT01258855
- Testing
- Aldesleukin, Laboratory Biomarker Analysis, Ziv-Aflibercept
- Where
- 21 sites in United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
High Risk Population of Gastric Cancer
Application of OE in Diagnosis of EGC
The main purpose of this study is to evaluate application value of OE mode 2 in the diagnosis of early gastric cancer The Secondary purpose is to evaluate application value of OE mode 1 in differentiating the diagnosis of…
- Trial name
- NCT04720521
- Testing
- OE+white light
- Where
- China
- Volunteers
- 2,454 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Other Skin
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
This phase I/II trial studies the side effects of gene-modified immune cells (FH-MCVA2TCR) and to see how well they work in treating patients with Merkel cell cancer that has spread to other parts of the body (metastatic) or that…
- Trial name
- NCT03747484
- Testing
- Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Avelumab, Pembrolizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Fred Hutchinson Cancer Center
Oropharyngeal Cancer
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
CompARE is a multicentre, phase III open-label randomised controlled trial using an adaptive, Multi-Arm, Multi-Stage (MAMS) design.
- Trial name
- CompARE (NCT04116047)
- Testing
- Cisplatin, Durvalumab, Radiotherapy
- Where
- 38 sites in Ireland, United Kingdom
- Volunteers
- 785 people
- Sponsor
- University of Birmingham
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.